K Szántó

Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade

Ákos Iliás, K Szántó, Lóránt Gönczi et al. · Clinical Gastroenterology and Hepatology · 2019 · 34 citations · Full text

Translational Medicine, Gastroenterology, Outcomes Research +5

Functional Anatomical Changes in Ulcerative Colitis Patients Determine Their Gut Microbiota Composition and Consequently the Possible Treatment Outcome

Anita Bálint, Klaudia Farkas, Orsolya Méhi et al. · Pharmaceuticals · 2020 · 25 citations · Full text

Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn’s disease and ulcerative colitis – experiences from a single center

Klaudia Farkas, Mariann Rutka, Tamás Ferenci et al. · Expert Opinion on Biological Therapy · 2017 · 24 citations

Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab – A prospective, multicenter cohort from Hungary

Lóránt Gönczi, K Szántó, Klaudia Farkas et al. · Digestive and Liver Disease · 2021 · 14 citations · Full text

Gastrointestinal Pharmacology, Medicine, Gastroenterology +7

Effects of bowel cleansing on the composition of the gut microbiota in inflammatory bowel disease patients and healthy controls

Péter Bacsúr, M Rutka, András Asbóth et al. · Therapeutic Advances in Gastroenterology · 2023 · 14 citations · Full text